Arcturus Therapeutics Holdings Inc. Common Stock ARCT
$14.46
-4.77%
at last close
Market Cap$431.75 million
P/E Ratio—
Div Yield—
Volume786.8K
52-Week Range
$5.50$24.17
Analyst Ratings
- Consensus
- Buy — 6 Buy · 2 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $21.00 (+45.2% upside)
Key Stats
- Today's Range
- $14.00 – $15.65
- 50-Day Range
- $5.50 – $16.59
- 52-Week Range
- $5.50 – $24.17
- Volume
- 787K shs
- Average Volume
- 1.07 million shs
- Market Cap
- $431.75 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.51
- Price / Sales
- 14.70
Short Interest
- Short Interest
- 0.22%
- Days to Cover
- 2.46
Financials (TTM)
- Revenue
- $29.37 million
- Net Income
- $-93,276,000
- Net Margin
- -317.62%
- Return on Equity
- -54.29%
- Debt-to-Equity
- —
About Arcturus Therapeutics Holdings Inc. Common Stock
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Related Stocks
Compare head-to-head: ARCT vs LLY·ARCT vs JNJ·ARCT vs ABBV·ARCT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.